Literature DB >> 26112428

Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus.

Lawrence Kleinberg1, Malcolm Brock, Michael Gibson.   

Abstract

Opinion statement: Adenocarcinoma of the esophagus is increasing in incidence in Western nations leading to increased interest in and opportunity to study optimal management. Randomized trials have now robustly demonstrated the preoperative therapy with chemoradiotherapy and chemotherapy alone improves survival outcome for the bulk of curable patients, those with locally advanced T1N1M0 and T2-3 N0-1 M0 disease. Evidence suggests but does not confirm that radiation-containing regimens are more beneficial. Clinical staging is designed to exclude patients with T1N0M0 disease who may be treated with surgery alone and those with metastatic disease who may not benefit from intensive local therapy. The approach to clinical staging includes endoscopy with ultrasound and fine needle aspirate to assess local and regional disease, supplemented by CT and PET scanning primarily to exclude metastatic disease. Minimally invasive approaches to esophagectomy may be used with the goal of reducing complications, but there is no evidence that mortality or ultimate outcome is improved.

Entities:  

Mesh:

Year:  2015        PMID: 26112428      PMCID: PMC4625398          DOI: 10.1007/s11864-015-0352-6

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  67 in total

Review 1.  Evidence-based guideline recommendations on the use of positron emission tomography imaging in oesophageal cancer.

Authors:  R Wong; C Walker-Dilks; A Raifu
Journal:  Clin Oncol (R Coll Radiol)       Date:  2011-09-29       Impact factor: 4.126

2.  Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.

Authors:  David H Ilson; Bruce D Minsky; Geoffrey Y Ku; Valerie Rusch; Nabil Rizk; Manish Shah; David P Kelsen; Marinela Capanu; Laura Tang; Jenny Campbell; Manjit Bains
Journal:  Cancer       Date:  2011-10-11       Impact factor: 6.860

Review 3.  Thoracoscopic versus robotic approaches: advantages and disadvantages.

Authors:  Benjamin Wei; Thomas A D'Amico
Journal:  Thorac Surg Clin       Date:  2014-05       Impact factor: 1.750

4.  Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.

Authors:  Vera Oppedijk; Ate van der Gaast; Jan J B van Lanschot; Pieter van Hagen; Rob van Os; Caroline M van Rij; Maurice J van der Sangen; Jannet C Beukema; Heidi Rütten; Patty H Spruit; Janny G Reinders; Dick J Richel; Mark I van Berge Henegouwen; Maarten C C M Hulshof
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

5.  Chemoradiotherapy, with adjuvant surgery for local control, confers a durable survival advantage in adenocarcinoma and squamous cell carcinoma of the oesophagus.

Authors:  G A Bass; H Furlong; K E O'Sullivan; T P J Hennessy; T N Walsh
Journal:  Eur J Cancer       Date:  2014-01-27       Impact factor: 9.162

6.  Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial.

Authors:  Surya S A Y Biere; Mark I van Berge Henegouwen; Kirsten W Maas; Luigi Bonavina; Camiel Rosman; Josep Roig Garcia; Suzanne S Gisbertz; Jean H G Klinkenbijl; Markus W Hollmann; Elly S M de Lange; H Jaap Bonjer; Donald L van der Peet; Miguel A Cuesta
Journal:  Lancet       Date:  2012-05-01       Impact factor: 79.321

7.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.

Authors:  T N Walsh; N Noonan; D Hollywood; A Kelly; N Keeling; T P Hennessy
Journal:  N Engl J Med       Date:  1996-08-15       Impact factor: 91.245

8.  Evaluation of performance of EUS-FNA in preoperative lymph node staging of cancers of esophagus, lung, and pancreas.

Authors:  H Q Peng; B D Greenwald; F R Tavora; E Kling; P Darwin; W H Rodgers; A Berry
Journal:  Diagn Cytopathol       Date:  2008-05       Impact factor: 1.582

9.  Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.

Authors:  David P Kelsen; Katryn A Winter; Leonard L Gunderson; Joanne Mortimer; Norman C Estes; Daniel G Haller; Jaffer A Ajani; Walter Kocha; Bruce D Minsky; Jack A Roth; Christopher G Willett
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

10.  Staging investigations for oesophageal cancer: a meta-analysis.

Authors:  E P M van Vliet; M H Heijenbrok-Kal; M G M Hunink; E J Kuipers; P D Siersema
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

View more
  3 in total

Review 1.  Esophageal cancer: The latest on chemoprevention and state of the art therapies.

Authors:  Gregoire F Le Bras; Muhammad H Farooq; Gary W Falk; Claudia D Andl
Journal:  Pharmacol Res       Date:  2016-08-24       Impact factor: 7.658

2.  Outcomes of the Surgical Treatment for Adenocarcinoma of the Cardia - Single Institution Experience.

Authors:  Stojan Potrc; Arpad Ivanecz; Bojan Krebs; Urska Marolt; Bojan Iljevec; Tomaz Jagric
Journal:  Radiol Oncol       Date:  2017-09-14       Impact factor: 2.991

3.  Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy.

Authors:  Gerd Jomrich; Dagmar Kollmann; Lavinia Wilfing; Sanja Radosavljevic; Dariga Ramazanova; Robin Ristl; Richard P Grose; Aysegül Ilhan-Mutlu; Matthias Preusser; Christina Fassnacht; Yi-Chien Tsai; Emmanuella Guenova; Sebastian F Schoppmann
Journal:  Eur Surg       Date:  2021-05-05       Impact factor: 0.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.